- Conditions
- Breast Cancer
- Interventions
- Omega-3 Fatty Acids, Placebo Capsule, Diet and Exercise
- Dietary Supplement · Other
- Lead sponsor
- Carol Fabian, MD
- Other
- Eligibility
- 45 Years to 70 Years · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2305–2328
of 5,062
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertriglyceridemia
- Interventions
- Simvastatin, acetylsalicylic acid (ASA), omefas
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Postmenopause
- Interventions
- Bazedoxifene 10 mg/CE 0.625 mg, Bazedoxifene 20 mg/CE 0.625 mg, Bazedoxifene 40 mg/CE 0.625 mg, Bazedoxifene 10 mg/CE 0.45 mg, Bazedoxifene 20 mg/CE 0.45 mg, Bazedoxifene 40 mg/CE 0.45 mg, Raloxifene 60 mg, Placebo
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 22
- States / cities
- Fort Myers, Florida • Gainesville, Florida • New Port Richey, Florida + 19 more
- Conditions
- Obsessive-compulsive Disorder, Ocd
- Interventions
- riluzole, placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Prostate Cancer
- Interventions
- lycopene supplement, fish oil supplement, Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Male only
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Post Traumatic Stress Disorder
- Interventions
- Psilocybin, Trauma-focused psychotherapy, Standard psychological support
- Drug · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Campylobacter Infection
- Interventions
- ALFQ, CJCV2
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Rheumatoid Arthritis
- Interventions
- PLX5622, Placebo
- Drug
- Lead sponsor
- Plexxikon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 4
- States / cities
- Anniston, Alabama • Lansing, Michigan • Duncansville, Pennsylvania + 1 more
- Conditions
- Pain
- Interventions
- Lidocaine, Bupivacaine
- Drug
- Lead sponsor
- University of Maryland
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Head and Neck Cancer
- Interventions
- thalidomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pembrolizumab, MK-4830, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab, Favezelimab/Pembrolizumab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 11
- States / cities
- San Francisco, California • New Haven, Connecticut • Chicago, Illinois + 7 more
- Conditions
- Disorder Related to Renal Transplantation
- Interventions
- Thymoglobulin, Belatacept, Sirolimus, Tacrolimus, Mycophenolate Mofetil (MMF)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 11
- States / cities
- San Francisco, California • Denver, Colorado • Augusta, Georgia + 7 more
- Conditions
- Tinea Pedis, Tinea Cruris
- Interventions
- Omeprazole 40 mg, Luliconazole Cream 1%
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Fair Lawn, New Jersey
- Conditions
- Gastrointestinal Neoplasms
- Interventions
- Ulixertinib, Hydroxychloroquine
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Autism Spectrum Disorder
- Interventions
- Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID], Placebo
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Lawrence, Kansas • White Plains, New York
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infections
- Interventions
- E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 583 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 41
- States / cities
- Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more
- Conditions
- Psoriasis
- Interventions
- LD-Aminopterin oral capsule, Placebo oral capsule
- Drug
- Lead sponsor
- Syntrix Biosystems, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Seattle, Washington • Spokane, Washington
- Conditions
- Cancer
- Interventions
- Dabrafenib, Trametinib, Panitumumab, 5-fluorouracil
- Drug · Device
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 4 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- SNDX-5613, Venetoclax, ASTX727
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
- Interventions
- HTD1801, Placebo
- Drug
- Lead sponsor
- HighTide Therapeutics (Hong Kong) Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 43
- States / cities
- Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
- Conditions
- Major Depressive Disorder
- Interventions
- Vilazodone, Placebo to citalopram, Placebo to vilazodone, Citalopram
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Scottsdale, Arizona + 46 more
- Conditions
- Sarcoma, Liposarcoma
- Interventions
- Palbociclib 200mg, Palbociclib 125mg
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Solid Tumors
- Interventions
- tivantinib, omeprazole, s-warfarin, caffeine, vitamin K, digoxin, midazolam
- Drug · Dietary Supplement
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Olaparib, 5-FU, Bevacizumab, Capecitabine, Leucovorin/ levoleucovorin
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 23
- States / cities
- Burbank, California • Fullerton, California • Colorado Springs, Colorado + 19 more